KAZIA THERAPEUTICS LTD (KZIA) was the issuer in an ownership amendment reporting that Dauntless Investment Group, LLC beneficially owned 842,340 American Depository Shares, or 5.42% of the class. Dauntless reported sole dispositive power over 842,340 shares and zero sole or shared voting power. Matthew Okkerse, identified as CFO, signed the amendment.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 10,700,211 American Depositary Shares (ADSs), each representing in total 5,350,105,500 Ordinary Shares, and updating its Form F-1 prospectus by incorporating a new Form 6-K. The ADSs trade on Nasdaq under the symbol KZIA, with a last reported price of $10.65 per ADS on September 21, 2026.
The incorporated Form 6-K announces that Sovargen Co. has dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders, triggering a $2 million development milestone payment to Kazia under their 2024 license agreement. Kazia is also eligible for up to an additional $17 million in future development and regulatory milestone payments, plus potential sub-licensing revenues and royalties on net sales.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 232,956 American Depositary Shares (ADSs) representing 116,478,000 ordinary shares, updating its Form F-1 prospectus by incorporating a new Form 6-K. The supplement attaches a report that includes a press release on a key development milestone for paxalisib.
The Form 6-K reports that Sovargen Co. has dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders, triggering a $2 million development milestone payment to Kazia under their licensing agreement. Kazia remains eligible for up to $17 million in additional development and regulatory milestones, plus potential sub-licensing revenues and royalties on future net sales.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 266,666 American Depositary Shares (ADSs), which represent 133,333,000 ordinary shares, and simultaneously updated the offering materials by incorporating a new Form 6-K. The supplement attaches a press release announcing that partner Sovargen Co. has dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders.
This first-patient dosing in mTORopathy-related epilepsies triggers a $2 million development milestone payment to Kazia under the licensing agreement and leaves Kazia eligible for up to $17 million in additional development and regulatory milestones, plus potential sub-licensing revenues and royalties on future net sales. The ADSs trade on Nasdaq under the symbol KZIA, and the last reported price on September 21, 2026 was $10.65 per ADS.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement related to an existing registration covering 95,110 American Depositary Shares representing 47,555,000 ordinary shares, and attached a current report describing a new clinical and financial milestone. The ADSs trade on Nasdaq, where they last closed at $10.65 per ADS on September 21, 2026.
The company reports that Sovargen Co. has dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders, triggering a $2 million development milestone payment to Kazia under their 2024 license agreement. Kazia is also eligible for up to $17 million in additional development and regulatory milestones, plus sub-licensing revenue and sales-based royalties.
Kazia Therapeutics Limited (KZIA) reports that Sovargen Co. has dosed the first patient in a Phase 1b/2a clinical trial of paxalisib for intractable epilepsy associated with focal cortical dysplasia type 2 and tuberous sclerosis complex. This dosing triggers a $2 million development milestone payment to Kazia under the companies’ exclusive license agreement.
Under this agreement, Sovargen is responsible for developing, manufacturing and commercializing paxalisib for mTORopathy-related epilepsies globally, excluding mainland China, Hong Kong, Macao and Taiwan. Kazia remains focused on oncology development of paxalisib and is eligible to receive up to $17 million in additional development and regulatory milestones, plus a percentage of sub-licensing revenues and royalties on net sales.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement updating a prior Form F-1 prospectus covering 266,666 American Depositary Shares (ADSs) representing 133,333,000 ordinary shares. The supplement incorporates a new Form 6-K describing changes to the company’s American Depositary Receipt (ADR) program.
Effective with this update, Kazia appointed JPMorgan Chase Bank, N.A. as sole depositary for its ADR program, replacing The Bank of New York Mellon, under a Second Amended and Restated Deposit Agreement. Each ADS represents 500 ordinary shares, and the ADSs continue trading on Nasdaq under the symbol KZIA. The company states that the transition should be seamless and that ADS holders do not need to take any action; existing positions remain in place. The last reported sale price on Nasdaq was $10.86 per ADS on September 17, 2026.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 232,956 American Depositary Shares (ADSs), which represent 116,478,000 ordinary shares, and updating its Form F-1 prospectus with a September 18, 2026 Form 6-K. The company has appointed JPMorgan Chase Bank, N.A. as sole depositary for its American Depositary Receipt program, replacing The Bank of New York Mellon. Under a Second Amended and Restated Deposit Agreement, each ADS now represents 500 ordinary shares, and the ADSs will continue to trade on Nasdaq under the symbol KZIA. Existing ADS holders are told no action is required and the transition is expected to be seamless.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement updating its Form F-1 prospectus covering 10,700,211 American Depositary Shares (ADSs), which are registered for offer and sale. Each ADS represents 500 ordinary shares, for a total of 5,350,105,500 ordinary shares underlying the ADSs.
The supplement attaches a Form 6-K describing the appointment of JPMorgan Chase Bank, N.A. as sole depositary for Kazia’s ADR program, replacing The Bank of New York Mellon. ADSs will continue trading on Nasdaq under the symbol KZIA, and existing ADS holders are expected to experience a seamless transition without needing to take any action.
Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 95,110 American Depositary Shares (ADSs), which represent 47,555,000 ordinary shares, and updating its prior Form F-1 prospectus with the contents of a new Form 6-K. The supplement attaches and incorporates the September 18, 2026 Form 6-K, which announces that Kazia has appointed JPMorgan Chase Bank, N.A. as sole depositary for its American Depositary Receipt program, replacing The Bank of New York Mellon. Under a Second Amended and Restated Deposit Agreement, each ADS will continue to represent 500 ordinary shares, and the ADSs will keep trading on the Nasdaq Capital Market under the symbol KZIA. On September 17, 2026, the last reported sale price of the ADSs was $10.86 per ADS. ADS holders are told they do not need to take any action and that the transition is expected to be seamless, with positions continuing without interruption.